Income StatementBalance SheetCash FlowSegments
Roivant Sciences logo

Roivant Sciences Income Statement

Revenue, expenses, and profitability over time

Roivant Sciences generated $8.3M in trailing twelve-month revenue, down 0.7% year-over-year. Based on the Q1 2026 filing.

Total Revenue (TTM)$8.3MOperating Income (TTM)-$1.2BNet Income (TTM)-$809.2MEps Diluted (TTM)$-1.17
Latest FilingQ1 2026
Report Date2026-05-20
Market Cap$20.4B

Operating Expenses

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Stock-Based Compensation Expense$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M
Share-Based Compensation Expense$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M
Depreciation and amortization$2.9M$1.4M$1.1M$921.0K$691.0K$638.0K
Operating Lease ROU Asset Amortization$1.7M$2.0M$1.9M$1.9M$2.5M$1.9M
Stock-based compensation expense$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M
Cost of revenues$259.0K$205.0K$154.0K$111.0K$700.0K$320.0K
Share-Based Compensation$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M
Amortization of Right-of-Use Assets$1.7M$2.0M$1.9M$1.9M$2.5M$1.9M

Other Income & Expense

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Other Non-Cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Gain (Loss) on Investments-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Other non-cash income (expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Gains on strategic investments, net-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Gain (loss) on disposal of assets-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Gains (losses) on equity investments-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Interest income$61.9M$54.6M$48.3M$45.3M$43.3M$41.2M
Other Non-Cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Gains on disposal of investments and other property-$21.3M$12.9M-$19.1M$128.5M$21.6M—
Other income (expense), net-$2.8M-$2.8M-$11.2M-$5.7M$8.3M$12.6M
Other Non-cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Other Non-Cash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——

Other

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Capital Expenditures$1.8M$811.0K$4.0M$7.8M—$1.3M
Change in Other Current Assets$41.7M—-$128.0K$4.4M$2.7M-$18.5M
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash——$815.0K$1.2M$430.0K$1.3M
Finance Lease Principal Payments$112.0K$0.0$0.0$0.0$0.0$0.0
Gain on sale of Telavant net assets$0.0$0.0$0.0$0.0$0.0$0.0
Increase (Decrease) in Accounts Payable, Trade—-$165.0K-$11.7M$3.0M-$4.0M$16.2M
Accrued liabilities-$3.0M—-$25.0M——$63.2M
Short- and long-term operating lease liabilities-$2.0M-$241.0K-$478.0K-$846.0K-$786.0K-$275.0K
Increase (Decrease) in Other Current Assets$41.7M—-$128.0K$4.4M$2.7M-$18.5M
Increase (Decrease) in Other Operating Assets and Liabilities, Net$6.4M—$71.0K$3.2M-$8.3M—
Issuance Of Subsidiary Shares In Connection With Debt Renegotiation$0.0$23.3M$0.0$0.0$0.0$0.0
Gain on litigation settlement$0.0$0.0$192.6M$192.6M$192.6M$192.6M
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation-$273.0M-$177.2M-$187.8M—$328.2M—
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation——-$1.1B———
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation-$207.3M-$172.6M-$204.4M-$185.7M-$196.5M-$163.8M
Noncash Other——$44.0K-$14.8M——
Operating lease right-of-use assets amortization expense$1.7M$2.0M$1.9M$1.9M$2.5M$1.9M
Other Noncash Income (Expense)-$11.9M-$4.2M-$11.1M-$6.0M——
Payments for Repurchase of Common Stock$243.3M$295.4M$208.3M———
Payments to Acquire Property, Plant, and Equipment$1.8M$811.0K$4.0M$7.8M—$1.3M
Cash received from option exercises$28.1M$12.6M$30.1M$68.3M$118.8M$51.2M
Stock-based compensation$83.7M$83.5M$82.2M$81.8M$105.0M$77.2M

Earnings Per Share

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Basic EPS from continuing operations$-0.22$-0.29$-0.33$-0.17$-0.38—
Diluted EPS from discontinued operations$0.45$0.01$0.00$0.00$0.00$0.00

Net Income

MetricQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26
Net income$169.4M-$206.5M-$223.4M-$113.5M-$265.9M—